XENETIC BIOSCIENCES

Xenetic Biosciences has extended its collaboration with Scripps Research and the laboratory of Dr. Alexey Stepanov by four months to further advance the development of combining systemic DNase I with CAR‑T cell therapies. The DNase‑I candidate XBIO‑015 is in preclinical development for hematologic and solid tumors; preclinical data show improved tumor control and survival when combined with CAR‑T. The program is moving into mechanism-of-action and translational studies, and the company is simultaneously planning a subscribed capital increase of 735,000 common shares at $6.12 per share (gross proceeds ~ $4.5 million). Financials show 12‑month revenue of $2.86 million, negative EBITDA of $3.27 million, but a current ratio of 4.56. » More on de.investing.com

Xenetic Biosciences issued 735,000 common shares at $6.12 each and expects gross proceeds of approximately $4.5 million from the placement before expenses. Canaccord Genuity is acting as sole bookrunner; closing is expected on or about October 14, 2025, and will be conducted on the basis of an S-3 shelf registration. The proceeds are to be used for working capital and general corporate purposes; concurrently, the company reports partnerships and studies to further develop its DNase oncology platform. » More on de.investing.com

Xenetic Biosciences, together with PeriNess Ltd., has initiated a clinical trial combining DNase I and anti-CD19 CAR-T cells in patients with large B-cell lymphoma. The study aims to evaluate the safety and efficacy of the combination therapy, following preclinical data that showed a significant reduction in tumor burden and prolonged survival. Additionally, Xenetic is expanding its research collaboration with the Scripps Research Institute to further develop its DNase-based oncology platform. » More on de.investing.com